WELL-MPN: A Digital Lifestyle App for Patients With MPNs

This study is looking at whether a digital app called WELL-MPN can help adults with myeloproliferative neoplasms (MPNs), which are a group of blood cancers. The app aims to improve diet, physical activity, symptoms, emotional well-being, and overall quality of life. Researchers want to see if people with MPNs can use the app effectively and if it leads to better lifestyle habits and fewer symptoms compared to receiving written educational materials. The study plans to enroll about 75 participants. To join, you must be at least 18 years old, have an MPN diagnosis, and be able to speak and understand English. The study's success will be measured by how many people use the app and complete its modules, and by participant satisfaction scores.

Study design
This is an interventional study that will compare participants using the WELL-MPN digital app with those receiving written educational materials. It plans to enroll about 75 adult participants.
What's involved
Participants randomized to the WELL-MPN arm will be given access to the WELL-MPN digital program (app) which provides lifestyle counseling through an iPad. The study measures satisfaction scores from enrollment to 16 weeks after enrollment.
Compensation
Not stated in the trial record.
Follow-up
The study measures participant satisfaction up to 16 weeks after enrollment, and app module completion up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07349134

WELL-MPN: A Digital Lifestyle App for Patients With MPNs

Not Yet Recruiting
NAAges 18+InterventionalSupportive care
Brigham and Women's Hospital
~75 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:WELL-MPN Digital App

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients consented and enrolled onto the study, and number of patients who complete at least 2 out of 3 modules in the app.
Measured over 2 years
+1 more outcome measured
Myeloproliferative Neoplasms (MPNs)
1 sites across 1 states
Massachusetts1
  • Chi-Joan How · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with a myeloproliferative neoplasm (MPN) by World Health Organization 2016 criteria
Adult (age \>/= 18)
Able to comprehend and speak English
Able to provide informed consent

Exclusion

Unable to comprehend and speak English
Unable to provide informed consent
  • Number of patients consented and enrolled onto the study, and number of patients who complete at least 2 out of 3 modules in the app.2 years

    Primary outcome is feasibility, defined as ≥60% enrollment of eligible patients and ≥70% of patients randomized to the intervention group completing at least 2 out of 3 of app modules.

  • 8-Item Client Satisfaction Scores (CSQ-8)Enrollment to 16 weeks after enrollment

    Acceptability of WELL-MPN as measured by CSQ-8 scores of WELL-MPN. The CSQ-8 is a self-report tool designed to measure patient satisfaction with a received intervention. It consists of 8 items rated on a 4-point Likert scale (from "quite dissatisfied" to "very satisfied"), with higher scores indicating greater satisfaction. WELL-MPN is considered acceptable if \>80% of participants on the WELL-MPN arm report a CSQ-8 score \>20.